BMC Pharmacology

Table 1 Treatment cohorts of the Tsc2^+/- mouse experiment.

From: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779

Treatment	Number of Mice	Time Period of Treatment	Age at Euthanization	Average Weight at Necropsy (g) (Ave. ± Std. Error)
Untreated	12 (6 M, 6 F)	N/A	12 months	34.0 ± 2.5
CCI-779	12 (6 M, 6 F)	2–4 months of age	12 months	33.4 ± 2.4
CCI-779 + IFN-γ	12 (6 M, 6 F)	2–4 months of age	12 months	32.1 ± 1.1
CCI-779	12 (6 M, 6 F)	6–8 months of age	12 months	31.7 ± 1.6
CCI-779 + IFN-γ	12 (6 M, 6 F)	6–8 months of age	12 months	29.2 ± 1.7
CCI-779	12 (6 M, 6 F)	10–12 months of age	12 months	30.5 ± 1.6
CCI-779 + IFN-γ	12 (6 M, 6 F)	10–12 months of age	12 months	28.6 ± 1.2

Back to article page